paratabs filmuhúðuð tafla 500 mg
teva b.v.* - paracetamolum inn - filmuhúðuð tafla - 500 mg
dolorin junior endaþarmsstíll 250 mg
williams & halls ehf.* - paracetamolum inn - endaþarmsstíll - 250 mg
paradorm (panadol night 500 mg/25 mg filmuhúðuð tafla) filmuhúðuð tafla 500 mg/25 mg
acare ehf. - paracetamolum inn; diphenhydraminum hýdróklóríð - filmuhúðuð tafla - 500 mg/25 mg
zercepac
accord healthcare s.l.u. - trastuzúmab - breast neoplasms; stomach neoplasms - Æxlishemjandi lyf - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Áður en lyfjameðferð hlýtur að hafa með að minnsta kosti anthracycline og taxane nema eru sjúklingar óhæf til þessara meðferða. hormón viðtaka jákvæð sjúklingar verða einnig að hafa ekki hormóna meðferð, nema eru sjúklingar óhæf til þessara meðferða. in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. ásamt docetaxel fyrir meðferð sjúklinga sem hafa ekki fengið lyfjameðferð fyrir sínum sjúklingum sjúkdómur. ásamt arómatasatálma fyrir meðferð tíðahvörf sjúklinga með hormón-viðtaka jákvæð bein, ekki áður meðhöndluð með trastuzumab. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). í kjölfar aðgerða, lyfjameðferð (formeðferð eða viðbótar) og geislameðferð (ef við). eftirfarandi viðbótar lyfjameðferð með doxórúbicíns og cýklófosfamíði, ásamt paclitaxel eða docetaxel. ásamt viðbótar lyfjameðferð samanstendur af docetaxel og carboplatín. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. nákvæm og staðfest prófi aðferðir ætti að nota.
parkódín filmuhúðuð tafla 500 mg/10 mg
teva b.v.* - paracetamolum inn; codeini phosphas hemihydricus - filmuhúðuð tafla - 500 mg/10 mg
panodil junior mixtúra, dreifa 24 mg/ml
haleon denmark aps - paracetamolum inn - mixtúra, dreifa - 24 mg/ml
panodil hot mixtúruduft, lausn 500 mg
haleon denmark aps - paracetamolum inn - mixtúruduft, lausn - 500 mg
panodil extra filmuhúðuð tafla 500/65 mg
haleon denmark aps - paracetamolum inn; coffeinum - filmuhúðuð tafla - 500/65 mg
paracet munndreifitafla 250 mg
karo pharma as - paracetamolum inn - munndreifitafla - 250 mg
parapró filmuhúðuð tafla 200/500 mg
acare ehf. - paracetamolum inn; ibuprofenum inn - filmuhúðuð tafla - 200/500 mg